This brand name is authorized in United States.
The drug ZIIHERA contains one active pharmaceutical ingredient (API):
1
|
UNII
Z20OC92TDI - ZANIDATAMAB
|
|
Zanidatamab is a dual HER2-targeted bispecific antibody that simultaneously binds extracellular domains 2 and 4 on separate HER2 monomers (binding in trans). Binding of zanidatamab with HER2 results in internalization leading to a reduction of the receptor on the cell surface. Zanidatamab induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumour growth inhibition and tumour cell death. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| ZIIHERA Powder for solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| ZIIHERA Powder for concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| US | FDA, National Drug Code | 68727-950 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.